Glaxosmithkline

SEP 10, 2026 · PHASE 1/2 TRIAL

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

ClinicalTrials.gov

This is a Phase 1/2 clinical trial registration with no posted results; it describes a planned early-phase study of a novel combination therapy in advanced solid tumors, designed primarily to establish safety and tolerability.

AUG 21, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Benlysta (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling change to belimumab; regulatory action affecting product information but does not report clinical trial efficacy data.

JUN 10, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Exdensur (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling change to Exdensur (depemokimab); regulatory action does not report clinical trial outcomes or efficacy data.

JUN 10, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Malarone (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval of labeling changes for an existing antimalarial drug; regulatory action without clinical trial data.